From: The role of IL-4 gene polymorphism in HCV-related hepatocellular carcinoma in Egyptian patients
 | Control (n = 30) | Cirrhosis (n = 40) | HCC (n = 50) | p value |
---|---|---|---|---|
Age (years)  Median (range) | 50.00 (40.00–59.00) | 52.5 (43.00–66.00) | 52.5 (42.00–67.00) | 0.066 |
Gender  Male (n, %)  Female (n, %) | 16 (53.3) 14 (46.7) | 22 (55.0) 18 (45.0) | 32 (64.0) 18 (36.0) | 0.562 |
ALT (U/L) Median (range) | 17.00 (9.0–36.0) | 48.50 (16.0–146.0) | 55.50 (20.0–102.0) | < 0.001 a,b |
AST (U/L)  Median (range) | 19.00 (9.0–36.0) | 60.50 (16.0–146.0) | 62.50 (20.0–102.0) | < 0.001 a,b |
Total bilirubin (mg/dL)  Median (range) | 0.50 (0.10–0.80) | 1.19 (0.45–4.18) | 1.50 (0.73–3.63) | < 0.001 a,b |
Direct bilirubin (mg/dL)  Median (range) | 0.10 (0.07–0.23) | 0.38 (0.09–3.08) | 0.62 (0.18–2.53) | < 0.001 a,b |
Albumin (g/dL)  Median (range) | 4.40 (3.50–5.10) | 3.68 (2.20–4.90) | 3.32 (2.20–4.52) | < 0.001 a,b |
Urea (mg/dL)  Median (range) | 27.50 (17.0–41.0) | 37.50 (22.0–56.0) | 38.00 (22.0–67.0) | < 0.001 a,b |
Creatinine (mg/dL)  Median (range) | 0.80 (0.50–1.20) | 0.87 (0.58–1.50) | 1.00 (0.50–1.50) | 0.001 a,b |